Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 5, 2021
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
[ Fri, Feb 05th 2021
] - WOPRAI
Keay Nakae Maintained (ARWR) at Strong Buy with Increased Target to $97 on, Feb 5th, 2021
Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $81 to $97 on, Feb 5th, 2021.
Keay has made no other calls on ARWR in the last 4 months.
There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Joel Beatty of "Baird" Downgraded from Buy to Hold on, Monday, December 21st, 2020
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $34 on, Tuesday, November 24th, 2020
This is the rating of the analyst that currently disagrees with Keay
- Shawn Egan of "Citigroup" Initiated at Strong Buy and Held Target at $90 on, Thursday, November 19th, 2020
